

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

C Number: C93025
Lock Date: 03/22/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

HISTORICAL CONTROL STUDIES From October 2007 Report

SAME ROUTE

- 96011-06 -- Cumene (INHALATION AIR)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

ALL ROUTES

- 88138-04 -- Benzophenone (ORAL FEED)
- 99027-04 -- Chromium picolinate monohydrate (ORAL FEED)
- 05174-06 -- Cresols (ORAL FEED)
- 96011-06 -- Cumene (INHALATION AIR)
- 97003-08 -- 1,2-Dibromo-2,4-dicyanobutane (SKIN ETHANOL)
- 93020-08 -- Diisopropylcarbodiimide (SKIN ETHANOL)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 88123-07 -- Formamide (GAVAGE WATER)
- 95011-06 -- 5-(Hydroxymethyl)-2-furfural (GAVAGE WATER)
- 88105-04 -- Isoeugenol (GAVAGE CORN OIL)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)
- 92012-06 -- 2-Methylimidazole (ORAL FEED)
- 92013-06 -- 4-Methylimidazole (ORAL FEED)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 99023-04 -- beta-Myrcene (GAVAGE CORN OIL)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 20114-06 -- Sodium dichromate dihydrate (VI) (ORAL WATER)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

**HISTORICAL CONTROL STUDIES
From October 2007 Report**

05109-14 -- Triethanolamine (SKIN ACETONE)

96019-06 -- Water disinfection byproducts (Bromochloroacetic acid) (ORAL WATER)

96018-04 -- Water disinfection byproducts (Bromodichloromethane) (ORAL WATER)

96017-06 -- Water disinfection byproducts (Dibromoacetic acid) (ORAL WATER)

96015-06 -- Water disinfection byproducts (Dibromoacetonitrile) (ORAL WATER)

96010-04 -- Water disinfection byproducts (Sodium chlorate) (ORAL WATER)

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

**FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.**

Adrenal Cortex
Adrenal Medulla
Bone Marrow
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pituitary Gland
Spleen
Thyroid Gland

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF Tetralin

MALE MICE

Organ

Harderian Gland
Islets, Pancreatic
All Organs

Morphology

Carcinoma
Adenoma
Hemangiosarcoma or Hemangioma
Benign Tumors
Malignant and Benign Tumors

FEMALE MICE

Organ

Liver
Lung

Spleen
All Organs

Morphology

Hepatocellular Carcinoma
Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Hemangiosarcoma
Benign Tumors
Malignant and Benign Tumors

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Adrenal Cortex
Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 2/49 (4%) | 0/49 (0%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b) | 2/44.17 | 0/44.56 | 1/45.72 | 2/44.37 |
| POLY-3 PERCENT (g) | 4.5% | 0% | 2.2% | 4.5% |
| TERMINAL (d) | 0/36 (0%) | 0/35 (0%) | 1/38 (3%) | 2/36 (6%) |
| FIRST INCIDENCE | 593 | --- | 729 (T) | 729 (T) |
| HC TUMORS SAME RTE | 11/297 (4%) | | | |
| HC TUMORS ALL RTES | 74/1142 (7%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.471 | P=0.235N | P=0.488N | P=0.692N |
| POLY 1.5 | P=0.473 | P=0.235N | P=0.489N | P=0.690N |
| POLY 6 | P=0.471 | P=0.237N | P=0.487N | P=0.694 |
| COCH-ARM / FISHERS | P=0.477 | P=0.247N | P=0.492N | P=0.684N |
| MAX-ISO-POLY-3 | P=0.416N | P=0.076N | P=0.273N | P=0.497N |
| HISTCONT SAME RTE | P=0.506 | (e) | P=1.000 | P=0.587 |
| HISTCONT ALL RTES | P=0.490 | (e) | P=1.000 | P=1.000 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Bone Marrow
Hemangiosarcoma**

TUMOR RATES

| | | | | |
|--------------------|-------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 1/49 (2%) | 0/50 (0%) | 2/49 (4%) |
| POLY-3 RATE (b) | 0/44.65 | 1/44.56 | 0/45.72 | 2/44.1 |
| POLY-3 PERCENT (g) | 0% | 2.2% | 0% | 4.5% |
| TERMINAL (d) | 0/36 (0%) | 1/35 (3%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | --- | 729 (T) | --- | 591 |
| HC TUMORS SAME RTE | 2/299 (1%) | | | |
| HC TUMORS ALL RTES | 8/1142 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|---------|-----|----------|
| POLY 3 | P=0.139 | P=0.500 | (e) | P=0.234 |
| POLY 1.5 | P=0.138 | P=0.499 | (e) | P=0.233 |
| POLY 6 | P=0.140 | P=0.499 | (e) | P=0.237 |
| COCH-ARM / FISHERS | P=0.137 | P=0.495 | (e) | P=0.242 |
| MAX-ISO-POLY-3 | P=0.076 | P=0.159 | (e) | P=0.075 |
| HISTCONT SAME RTE | P=0.089 | P=0.199 | (e) | P=0.090 |
| HISTCONT ALL RTES | P=0.053 | P=0.190 | (e) | P=0.034* |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|--------------------------------|----------------|------------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Harderian Gland Adenoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 2/50 (4%) | 5/50 (10%) | 4/50 (8%) | 1/50 (2%) |
| POLY-3 RATE (b) | 2/45.12 | 5/45.51 | 4/45.99 | 1/44.37 |
| POLY-3 PERCENT (g) | 4.4% | 11% | 8.7% | 2.3% |
| TERMINAL (d) | 1/36 (3%) | 4/35 (11%) | 3/38 (8%) | 1/36 (3%) |
| FIRST INCIDENCE | 593 | 602 | 656 | 729 (T) |
| HC TUMORS SAME RTE | 38/300 (13%) | | | |
| HC TUMORS ALL RTES | 152/1149 (13%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|---------|----------|
| POLY 3 | P=0.281N | P=0.219 | P=0.346 | P=0.506N |
| POLY 1.5 | P=0.278N | P=0.220 | P=0.343 | P=0.503N |
| POLY 6 | P=0.284N | P=0.216 | P=0.349 | P=0.508N |
| COCH-ARM / FISHERS | P=0.273N | P=0.218 | P=0.339 | P=0.500N |
| MAX-ISO-POLY-3 | P=0.222N | P=0.123 | P=0.210 | P=0.287N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|----------------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Harderian Gland Carcinoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 3/50 (6%) | 3/50 (6%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b) | 3/44.65 | 3/45.07 | 0/45.72 | 1/44.37 |
| POLY-3 PERCENT (g) | 6.7% | 6.7% | 0% | 2.3% |
| TERMINAL (d) | 3/36 (8%) | 3/35 (9%) | 0/38 (0%) | 1/36 (3%) |
| FIRST INCIDENCE | 729 (T) | 729 (T) | --- | 729 (T) |
| HC TUMORS SAME RTE | 11/300 (4%) | | | |
| HC TUMORS ALL RTES | 30/1149 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|-----------|----------|
| POLY 3 | P=0.133N | P=0.658N | P=0.114N | P=0.307N |
| POLY 1.5 | P=0.134N | P=0.658N | P=0.116N | P=0.307N |
| POLY 6 | P=0.132N | P=0.661N | P=0.113N | P=0.307N |
| COCH-ARM / FISHERS | P=0.134N | P=0.661N | P=0.121N | P=0.309N |
| MAX-ISO-POLY-3 | P=0.137N | P=0.495N | P=0.038N* | P=0.156N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|---|----------------|------------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Harderian Gland Carcinoma or Adenoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 5/50 (10%) | 8/50 (16%) | 4/50 (8%) | 2/50 (4%) |
| POLY-3 RATE (b) | 5/45.12 | 8/45.51 | 4/45.99 | 2/44.37 |
| POLY-3 PERCENT (g) | 11.1% | 17.6% | 8.7% | 4.5% |
| TERMINAL (d) | 4/36 (11%) | 7/35 (20%) | 3/38 (8%) | 2/36 (6%) |
| FIRST INCIDENCE | 593 | 602 | 656 | 729 (T) |
| HC TUMORS SAME RTE | 48/300 (16%) | | | |
| HC TUMORS ALL RTES | 176/1149 (15%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.092N | P=0.280 | P=0.488N | P=0.223N |
| POLY 1.5 | P=0.091N | P=0.281 | P=0.492N | P=0.220N |
| POLY 6 | P=0.092N | P=0.275 | P=0.483N | P=0.225N |
| COCH-ARM / FISHERS | P=0.089N | P=0.277 | P=0.500N | P=0.218N |
| MAX-ISO-POLY-3 | P=0.104N | P=0.190 | P=0.352N | P=0.126N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Islets, Pancreatic
Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 2/49 (4%) | 0/48 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 2/44.06 | 0/43.93 | 0/45.72 | 0/44.37 |
| POLY-3 PERCENT (g) | 4.5% | 0% | 0% | 0% |
| TERMINAL (d) | 1/36 (3%) | 0/35 (0%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 618 | --- | --- | --- |
| HC TUMORS SAME RTE | 3/295 (1%) | | | |
| HC TUMORS ALL RTES | 11/1136 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----------|----------|----------|----------|
| POLY 3 | P=0.111N | P=0.238N | P=0.229N | P=0.235N |
| POLY 1.5 | P=0.111N | P=0.239N | P=0.230N | P=0.234N |
| POLY 6 | P=0.111N | P=0.238N | P=0.228N | P=0.236N |
| COCH-ARM / FISHERS | P=0.112N | P=0.253N | P=0.242N | P=0.242N |
| MAX-ISO-POLY-3 | P=0.032N* | P=0.077N | P=0.075N | P=0.075N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Islets, Pancreatic
Carcinoma or Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 2/49 (4%) | 0/48 (0%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b) | 2/44.06 | 0/43.93 | 1/45.72 | 0/44.37 |
| POLY-3 PERCENT (g) | 4.5% | 0% | 2.2% | 0% |
| TERMINAL (d) | 1/36 (3%) | 0/35 (0%) | 1/38 (3%) | 0/36 (0%) |
| FIRST INCIDENCE | 618 | --- | 729 (T) | --- |
| HC TUMORS SAME RTE | 4/295 (1%) | | | |
| HC TUMORS ALL RTES | 12/1136 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.187N | P=0.238N | P=0.487N | P=0.235N |
| POLY 1.5 | P=0.186N | P=0.239N | P=0.489N | P=0.234N |
| POLY 6 | P=0.187N | P=0.238N | P=0.486N | P=0.236N |
| COCH-ARM / FISHERS | P=0.183N | P=0.253N | P=0.492N | P=0.242N |
| MAX-ISO-POLY-3 | P=0.078N | P=0.077N | P=0.272N | P=0.075N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hemangiosarcoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 1/49 (2%) | 3/50 (6%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b) | 1/44.13 | 3/45.21 | 0/45.72 | 1/44.84 |
| POLY-3 PERCENT (g) | 2.3% | 6.6% | 0% | 2.2% |
| TERMINAL (d) | 0/36 (0%) | 1/35 (3%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 592 | 705 | --- | 591 |
| HC TUMORS SAME RTE | 10/299 (3%) | | | |
| HC TUMORS ALL RTES | 30/1146 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.403N | P=0.314 | P=0.493N | P=0.757N |
| POLY 1.5 | P=0.403N | P=0.314 | P=0.494N | P=0.757N |
| POLY 6 | P=0.403N | P=0.310 | P=0.492N | P=0.757N |
| COCH-ARM / FISHERS | P=0.404N | P=0.316 | P=0.495N | P=0.747N |
| MAX-ISO-POLY-3 | P=0.271N | P=0.162 | P=0.157N | P=0.495N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|-------------------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Liver | | | | |
| Hepatocellular Adenoma | | | | |
| TUMOR RATES | | | | |
| OVERALL (a) | 33/49 (67%) | 31/50 (62%) | 35/50 (70%) | 27/50 (54%) |
| POLY-3 RATE (b) | 33/44.98 | 31/47.97 | 35/48.98 | 27/45.73 |
| POLY-3 PERCENT (g) | 73.4% | 64.6% | 71.5% | 59% |
| TERMINAL (d) | 29/36 (81%) | 24/35 (69%) | 26/38 (68%) | 21/36 (58%) |
| FIRST INCIDENCE | 516 | 454 | 493 | 591 |
| HC TUMORS SAME RTE | 141/299 (47%) | | | |
| HC TUMORS ALL RTEs | 544/1146 (48%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.124N | P=0.239N | P=0.510N | P=0.102N |
| POLY 1.5 | P=0.127N | P=0.284N | P=0.587N | P=0.112N |
| POLY 6 | P=0.110N | P=0.200N | P=0.416N | P=0.087N |
| COCH-ARM / FISHERS | P=0.124N | P=0.365N | P=0.473 | P=0.124N |
| MAX-ISO-POLY-3 | P=0.112N | P=0.180N | P=0.417N | P=0.067N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTEs | (h) | (h) | (h) | (h) |

TDMS No. 93025 - 06
 Test Type: CHRONIC
 Route: RESPIRATORY EXPOSURE WHOLE BODY
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin
 CAS Number: 119-64-2

Date Report Requested: 05/22/2008
 Time Report Requested: 06:34:08
 First Dose M/F: 06/23/03 / 06/23/03
 Lab: BNW

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
 Hepatocellular Carcinoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 11/49 (22%) | 17/50 (34%) | 14/50 (28%) | 14/50 (28%) |
| POLY-3 RATE (b) | 11/46.73 | 17/47.9 | 14/47.77 | 14/47.96 |
| POLY-3 PERCENT (g) | 23.5% | 35.5% | 29.3% | 29.2% |
| TERMINAL (d) | 5/36 (14%) | 9/35 (26%) | 8/38 (21%) | 6/36 (17%) |
| FIRST INCIDENCE | 422 | 454 | 593 | 478 |
| HC TUMORS SAME RTE | 74/299 (25%) | | | |
| HC TUMORS ALL RTES | 317/1146 (28%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|---------|---------|---------|
| POLY 3 | P=0.443 | P=0.146 | P=0.344 | P=0.349 |
| POLY 1.5 | P=0.438 | P=0.148 | P=0.343 | P=0.345 |
| POLY 6 | P=0.455 | P=0.143 | P=0.350 | P=0.356 |
| COCH-ARM / FISHERS | P=0.436 | P=0.146 | P=0.343 | P=0.343 |
| MAX-ISO-POLY-3 | P=0.332 | P=0.102 | P=0.265 | P=0.269 |
| HISTCONT SAME RTE | P=0.396 | P=0.111 | P=0.342 | P=0.348 |
| HISTCONT ALL RTES | P=0.385 | P=0.118 | P=0.329 | P=0.335 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hepatocellular Carcinoma or Hepatocellular Adenoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 37/49 (76%) | 40/50 (80%) | 40/50 (80%) | 35/50 (70%) |
| POLY-3 RATE (b) | 37/46.96 | 40/49.17 | 40/49.86 | 35/48.16 |
| POLY-3 PERCENT (g) | 78.8% | 81.4% | 80.2% | 72.7% |
| TERMINAL (d) | 29/36 (81%) | 28/35 (80%) | 29/38 (76%) | 25/36 (69%) |
| FIRST INCIDENCE | 422 | 454 | 493 | 478 |
| HC TUMORS SAME RTE | 185/299 (62%) | | | |
| HC TUMORS ALL RTES | 729/1146 (64%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.222N | P=0.476 | P=0.531 | P=0.321N |
| POLY 1.5 | P=0.233N | P=0.440 | P=0.470 | P=0.336N |
| POLY 6 | P=0.200N | P=0.513 | P=0.601N | P=0.295N |
| COCH-ARM / FISHERS | P=0.237N | P=0.384 | P=0.384 | P=0.349N |
| MAX-ISO-POLY-3 | P=0.304N | P=0.374 | P=0.430 | P=0.242N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 37/49 (76%) | 40/50 (80%) | 40/50 (80%) | 35/50 (70%) |
| POLY-3 RATE (b) | 37/46.96 | 40/49.17 | 40/49.86 | 35/48.16 |
| POLY-3 PERCENT (g) | 78.8% | 81.4% | 80.2% | 72.7% |
| TERMINAL (d) | 29/36 (81%) | 28/35 (80%) | 29/38 (76%) | 25/36 (69%) |
| FIRST INCIDENCE | 422 | 454 | 493 | 478 |
| HC TUMORS SAME RTE | 186/299 (62%) | | | |
| HC TUMORS ALL RTES | 740/1146 (65%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.222N | P=0.476 | P=0.531 | P=0.321N |
| POLY 1.5 | P=0.233N | P=0.440 | P=0.470 | P=0.336N |
| POLY 6 | P=0.200N | P=0.513 | P=0.601N | P=0.295N |
| COCH-ARM / FISHERS | P=0.237N | P=0.384 | P=0.384 | P=0.349N |
| MAX-ISO-POLY-3 | P=0.304N | P=0.374 | P=0.430 | P=0.242N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Lung
Alveolar/Bronchiolar Adenoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|------------|------------|------------|
| OVERALL (a) | 10/50 (20%) | 6/50 (12%) | 6/50 (12%) | 8/50 (16%) |
| POLY-3 RATE (b) | 10/45.93 | 6/45.16 | 6/45.86 | 8/45.15 |
| POLY-3 PERCENT (g) | 21.8% | 13.3% | 13.1% | 17.7% |
| TERMINAL (d) | 7/36 (19%) | 5/35 (14%) | 5/38 (13%) | 7/36 (19%) |
| FIRST INCIDENCE | 422 | 705 | 694 | 444 |
| HC TUMORS SAME RTE | 58/299 (19%) | | | |
| HC TUMORS ALL RTES | 209/1148 (18%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.426N | P=0.215N | P=0.205N | P=0.412N |
| POLY 1.5 | P=0.425N | P=0.211N | P=0.206N | P=0.407N |
| POLY 6 | P=0.425N | P=0.223N | P=0.204N | P=0.417N |
| COCH-ARM / FISHERS | P=0.420N | P=0.207N | P=0.207N | P=0.398N |
| MAX-ISO-POLY-3 | P=0.295N | P=0.145N | P=0.136N | P=0.315N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Lung
Alveolar/Bronchiolar Carcinoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|------------|-------------|------------|
| OVERALL (a) | 11/50 (22%) | 7/50 (14%) | 12/50 (24%) | 8/50 (16%) |
| POLY-3 RATE (b) | 11/45.33 | 7/45.07 | 12/45.77 | 8/44.37 |
| POLY-3 PERCENT (g) | 24.3% | 15.5% | 26.2% | 18% |
| TERMINAL (d) | 8/36 (22%) | 7/35 (20%) | 11/38 (29%) | 8/36 (22%) |
| FIRST INCIDENCE | 618 | 729 (T) | 716 | 729 (T) |
| HC TUMORS SAME RTE | 38/299 (13%) | | | |
| HC TUMORS ALL RTES | 115/1148 (10%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|---------|----------|
| POLY 3 | P=0.397N | P=0.218N | P=0.511 | P=0.321N |
| POLY 1.5 | P=0.391N | P=0.216N | P=0.508 | P=0.314N |
| POLY 6 | P=0.401N | P=0.229N | P=0.509 | P=0.330N |
| COCH-ARM / FISHERS | P=0.380N | P=0.218N | P=0.500 | P=0.306N |
| MAX-ISO-POLY-3 | P=0.383N | P=0.149N | P=0.414 | P=0.238N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Lung
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 20/50 (40%) | 13/50 (26%) | 18/50 (36%) | 14/50 (28%) |
| POLY-3 RATE (b) | 20/46.6 | 13/45.16 | 18/45.91 | 14/45.15 |
| POLY-3 PERCENT (g) | 42.9% | 28.8% | 39.2% | 31% |
| TERMINAL (d) | 14/36 (39%) | 12/35 (34%) | 16/38 (42%) | 13/36 (36%) |
| FIRST INCIDENCE | 422 | 705 | 694 | 444 |
| HC TUMORS SAME RTE | 92/299 (31%) | | | |
| HC TUMORS ALL RTES | 309/1148 (27%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.230N | P=0.113N | P=0.440N | P=0.165N |
| POLY 1.5 | P=0.224N | P=0.106N | P=0.430N | P=0.156N |
| POLY 6 | P=0.236N | P=0.129N | P=0.454N | P=0.178N |
| COCH-ARM / FISHERS | P=0.214N | P=0.101N | P=0.418N | P=0.146N |
| MAX-ISO-POLY-3 | P=0.187N | P=0.080N | P=0.358N | P=0.121N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Mammary Gland
Carcinoma**

TUMOR RATES

| | # | # | # | # |
|--------------------|-------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 0/44.65 | 0/45.07 | 0/45.72 | 0/44.37 |
| POLY-3 PERCENT (g) | 0% | 0% | 0% | 0% |
| TERMINAL (d) | 0/36 (0%) | 0/35 (0%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | --- | --- | --- | --- |
| HC TUMORS SAME RTE | 0/300 (0%) | | | |
| HC TUMORS ALL RTES | 1/1149 (0%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----|-----|-----|-----|
| POLY 3 | (e) | (e) | (e) | (e) |
| POLY 1.5 | (e) | (e) | (e) | (e) |
| POLY 6 | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3 | (e) | (e) | (e) | (e) |
| HISTCONT SAME RTE | (e) | (e) | (e) | (e) |
| HISTCONT ALL RTES | (e) | (e) | (e) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma**

TUMOR RATES

| | | | | |
|--------------------|-------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 1/49 (2%) | 0/48 (0%) | 0/49 (0%) |
| POLY-3 RATE (b) | 0/44.65 | 1/44.56 | 0/45.04 | 0/43.37 |
| POLY-3 PERCENT (g) | 0% | 2.2% | 0% | 0% |
| TERMINAL (d) | 0/36 (0%) | 1/35 (3%) | 0/38 (0%) | 0/35 (0%) |
| FIRST INCIDENCE | --- | 729 (T) | --- | --- |
| HC TUMORS SAME RTE | 1/290 (0%) | | | |
| HC TUMORS ALL RTES | 3/1119 (0%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|-----|-----|
| POLY 3 | P=0.564N | P=0.500 | (e) | (e) |
| POLY 1.5 | P=0.566N | P=0.499 | (e) | (e) |
| POLY 6 | P=0.563N | P=0.499 | (e) | (e) |
| COCH-ARM / FISHERS | P=0.570N | P=0.495 | (e) | (e) |
| MAX-ISO-POLY-3 | P=0.397N | P=0.159 | (e) | (e) |
| HISTCONT SAME RTE | (h) | (h) | (e) | (e) |
| HISTCONT ALL RTES | (h) | (h) | (e) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Skin
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 2/50 (4%) | 1/50 (2%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 2/44.65 | 1/45.07 | 0/45.72 | 0/44.37 |
| POLY-3 PERCENT (g) | 4.5% | 2.2% | 0% | 0% |
| TERMINAL (d) | 2/36 (6%) | 1/35 (3%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 729 (T) | 729 (T) | --- | --- |
| HC TUMORS SAME RTE | 7/300 (2%) | | | |
| HC TUMORS ALL RTES | 14/1149 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.100N | P=0.497N | P=0.232N | P=0.238N |
| POLY 1.5 | P=0.100N | P=0.497N | P=0.234N | P=0.238N |
| POLY 6 | P=0.099N | P=0.499N | P=0.230N | P=0.238N |
| COCH-ARM / FISHERS | P=0.101N | P=0.500N | P=0.247N | P=0.247N |
| MAX-ISO-POLY-3 | P=0.079N | P=0.279N | P=0.076N | P=0.077N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Skin
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 2/50 (4%) | 1/50 (2%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 2/44.65 | 1/45.07 | 0/45.72 | 0/44.37 |
| POLY-3 PERCENT (g) | 4.5% | 2.2% | 0% | 0% |
| TERMINAL (d) | 2/36 (6%) | 1/35 (3%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 729 (T) | 729 (T) | --- | --- |
| HC TUMORS SAME RTE | 7/300 (2%) | | | |
| HC TUMORS ALL RTES | 11/1149 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.100N | P=0.497N | P=0.232N | P=0.238N |
| POLY 1.5 | P=0.100N | P=0.497N | P=0.234N | P=0.238N |
| POLY 6 | P=0.099N | P=0.499N | P=0.230N | P=0.238N |
| COCH-ARM / FISHERS | P=0.101N | P=0.500N | P=0.247N | P=0.247N |
| MAX-ISO-POLY-3 | P=0.079N | P=0.279N | P=0.076N | P=0.077N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------------------------|-------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Skin | | | | |
| Hemangiosarcoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 2/50 (4%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b) | 2/44.9 | 1/45.07 | 1/45.84 | 1/44.47 |
| POLY-3 PERCENT (g) | 4.5% | 2.2% | 2.2% | 2.3% |
| TERMINAL (d) | 1/36 (3%) | 1/35 (3%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 663 | 729 (T) | 700 | 705 |
| HC TUMORS SAME RTE | 1/300 (0%) | | | |
| HC TUMORS ALL RTES | 7/1149 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.411N | P=0.499N | P=0.493N | P=0.503N |
| POLY 1.5 | P=0.411N | P=0.498N | P=0.495N | P=0.502N |
| POLY 6 | P=0.410N | P=0.503N | P=0.491N | P=0.504N |
| COCH-ARM / FISHERS | P=0.409N | P=0.500N | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3 | P=0.423N | P=0.280N | P=0.276N | P=0.284N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Spleen
Hemangiosarcoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 1/49 (2%) | 0/49 (0%) | 0/49 (0%) | 2/49 (4%) |
| POLY-3 RATE (b) | 1/43.67 | 0/44.56 | 0/45.41 | 2/44.65 |
| POLY-3 PERCENT (g) | 2.3% | 0% | 0% | 4.5% |
| TERMINAL (d) | 1/36 (3%) | 0/35 (0%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 729 (T) | --- | --- | 591 |
| HC TUMORS SAME RTE | 4/297 (1%) | | | |
| HC TUMORS ALL RTES | 21/1136 (2%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|----------|---------|
| POLY 3 | P=0.247 | P=0.496N | P=0.492N | P=0.508 |
| POLY 1.5 | P=0.246 | P=0.497N | P=0.495N | P=0.504 |
| POLY 6 | P=0.249 | P=0.496N | P=0.489N | P=0.513 |
| COCH-ARM / FISHERS | P=0.246 | P=0.500N | P=0.500N | P=0.500 |
| MAX-ISO-POLY-3 | P=0.142 | P=0.158N | P=0.158N | P=0.289 |
| HISTCONT SAME RTE | P=0.106 | (e) | (e) | P=0.082 |
| HISTCONT ALL RTES | P=0.163 | (e) | (e) | P=0.175 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Stomach, Forestomach
Squamous Cell Papilloma**

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b) | 0/44.65 | 0/45.07 | 0/45.72 | 1/44.37 |
| POLY-3 PERCENT (g) | 0% | 0% | 0% | 2.3% |
| TERMINAL (d) | 0/36 (0%) | 0/35 (0%) | 0/38 (0%) | 1/36 (3%) |
| FIRST INCIDENCE | --- | --- | --- | 729 (T) |
| HC TUMORS SAME RTE | 2/300 (1%) | | | |
| HC TUMORS ALL RTES | 11/1149 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|-----|-----|---------|
| POLY 3 | P=0.198 | (e) | (e) | P=0.499 |
| POLY 1.5 | P=0.198 | (e) | (e) | P=0.499 |
| POLY 6 | P=0.198 | (e) | (e) | P=0.499 |
| COCH-ARM / FISHERS | P=0.198 | (e) | (e) | P=0.500 |
| MAX-ISO-POLY-3 | P=0.124 | (e) | (e) | P=0.158 |
| HISTCONT SAME RTE | (e) | (e) | (e) | (e) |
| HISTCONT ALL RTES | (e) | (e) | (e) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------------------------|--------------|------------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Hemangiosarcoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 4/50 (8%) | 5/50 (10%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b) | 4/45.37 | 5/45.21 | 1/45.84 | 2/44.94 |
| POLY-3 PERCENT (g) | 8.8% | 11.1% | 2.2% | 4.5% |
| TERMINAL (d) | 2/36 (6%) | 3/35 (9%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 592 | 705 | 700 | 591 |
| HC TUMORS SAME RTE | 16/300 (5%) | | | |
| HC TUMORS ALL RTES | 67/1149 (6%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.157N | P=0.498 | P=0.175N | P=0.341N |
| POLY 1.5 | P=0.158N | P=0.501 | P=0.177N | P=0.340N |
| POLY 6 | P=0.157N | P=0.489 | P=0.175N | P=0.342N |
| COCH-ARM / FISHERS | P=0.157N | P=0.500 | P=0.181N | P=0.339N |
| MAX-ISO-POLY-3 | P=0.164N | P=0.361 | P=0.083N | P=0.205N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|--------------------------------------|--------------|------------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Hemangiosarcoma or Hemangioma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 5/50 (10%) | 5/50 (10%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b) | 5/45.37 | 5/45.21 | 1/45.84 | 2/44.94 |
| POLY-3 PERCENT (g) | 11% | 11.1% | 2.2% | 4.5% |
| TERMINAL (d) | 3/36 (8%) | 3/35 (9%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | 592 | 705 | 700 | 591 |
| HC TUMORS SAME RTE | 19/300 (6%) | | | |
| HC TUMORS ALL RTES | 76/1149 (7%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|-----------|----------|
| POLY 3 | P=0.095N | P=0.628 | P=0.099N | P=0.220N |
| POLY 1.5 | P=0.095N | P=0.629N | P=0.100N | P=0.219N |
| POLY 6 | P=0.094N | P=0.620 | P=0.098N | P=0.220N |
| COCH-ARM / FISHERS | P=0.095N | P=0.630N | P=0.102N | P=0.218N |
| MAX-ISO-POLY-3 | P=0.123N | P=0.497 | P=0.044N* | P=0.123N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|----------------------------|-------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Histiocytic Sarcoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 0/44.65 | 0/45.07 | 0/45.72 | 0/44.37 |
| POLY-3 PERCENT (g) | 0% | 0% | 0% | 0% |
| TERMINAL (d) | 0/36 (0%) | 0/35 (0%) | 0/38 (0%) | 0/36 (0%) |
| FIRST INCIDENCE | --- | --- | --- | --- |
| HC TUMORS SAME RTE | 3/300 (1%) | | | |
| HC TUMORS ALL RTES | 7/1149 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----|-----|-----|-----|
| POLY 3 | (e) | (e) | (e) | (e) |
| POLY 1.5 | (e) | (e) | (e) | (e) |
| POLY 6 | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3 | (e) | (e) | (e) | (e) |
| HISTCONT SAME RTE | (e) | (e) | (e) | (e) |
| HISTCONT ALL RTES | (e) | (e) | (e) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

All Organs
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 2/50 (4%) | 1/50 (2%) | 4/50 (8%) | 2/50 (4%) |
| POLY-3 RATE (b) | 2/44.65 | 1/45.07 | 4/45.77 | 2/44.37 |
| POLY-3 PERCENT (g) | 4.5% | 2.2% | 8.7% | 4.5% |
| TERMINAL (d) | 2/36 (6%) | 1/35 (3%) | 3/38 (8%) | 2/36 (6%) |
| FIRST INCIDENCE | 729 (T) | 729 (T) | 716 | 729 (T) |
| HC TUMORS SAME RTE | 8/300 (3%) | | | |
| HC TUMORS ALL RTES | 34/1149 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|---------|----------|
| POLY 3 | P=0.471 | P=0.497N | P=0.349 | P=0.692 |
| POLY 1.5 | P=0.472 | P=0.497N | P=0.345 | P=0.692 |
| POLY 6 | P=0.473 | P=0.499N | P=0.353 | P=0.692 |
| COCH-ARM / FISHERS | P=0.477 | P=0.500N | P=0.339 | P=0.691N |
| MAX-ISO-POLY-3 | P=0.387 | P=0.279N | P=0.212 | P=0.497 |
| HISTCONT SAME RTE | P=0.292 | P=1.000 | P=0.084 | P=0.391 |
| HISTCONT ALL RTES | P=0.225 | P=1.000 | P=0.051 | P=0.424 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|----------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Benign Tumors | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 42/50 (84%) | 36/50 (72%) | 38/50 (76%) | 31/50 (62%) |
| POLY-3 RATE (b) | 42/48.43 | 36/48.07 | 38/49.12 | 31/46.51 |
| POLY-3 PERCENT (g) | 86.7% | 74.9% | 77.4% | 66.7% |
| TERMINAL (d) | 32/36 (89%) | 28/35 (80%) | 28/38 (74%) | 24/36 (67%) |
| FIRST INCIDENCE | 422 | 454 | 493 | 444 |
| HC TUMORS SAME RTE | 200/300 (67%) | | | |
| HC TUMORS ALL RTES | 753/1149 (66%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----------|----------|----------|------------|
| POLY 3 | P=0.019N* | P=0.101N | P=0.168N | P=0.014N* |
| POLY 1.5 | P=0.017N* | P=0.102N | P=0.188N | P=0.012N* |
| POLY 6 | P=0.021N* | P=0.113N | P=0.148N | P=0.017N* |
| COCH-ARM / FISHERS | P=0.014N* | P=0.114N | P=0.227N | P=0.012N* |
| MAX-ISO-POLY-3 | P=0.015N* | P=0.061N | P=0.109N | P=0.008N** |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|-------------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Malignant Tumors | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 26/50 (52%) | 27/50 (54%) | 24/50 (48%) | 26/50 (52%) |
| POLY-3 RATE (b) | 26/48.14 | 27/48.83 | 24/47.82 | 26/48.83 |
| POLY-3 PERCENT (g) | 54% | 55.3% | 50.2% | 53.3% |
| TERMINAL (d) | 18/36 (50%) | 15/35 (43%) | 17/38 (45%) | 16/36 (44%) |
| FIRST INCIDENCE | 422 | 454 | 593 | 444 |
| HC TUMORS SAME RTE | 146/300 (49%) | | | |
| HC TUMORS ALL RTEs | 582/1149 (51%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.471N | P=0.531 | P=0.432N | P=0.551N |
| POLY 1.5 | P=0.479N | P=0.520 | P=0.429N | P=0.562N |
| POLY 6 | P=0.459N | P=0.542 | P=0.430N | P=0.537N |
| COCH-ARM / FISHERS | P=0.490N | P=0.500 | P=0.421N | P=0.579N |
| MAX-ISO-POLY-3 | P=0.605N | P=0.449 | P=0.353N | P=0.469N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTEs | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Males | | | |
|------------------------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Malignant and Benign Tumors | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 47/50 (94%) | 46/50 (92%) | 46/50 (92%) | 42/50 (84%) |
| POLY-3 RATE (b) | 47/49.14 | 46/50 | 46/50 | 42/49.02 |
| POLY-3 PERCENT (g) | 95.6% | 92% | 92% | 85.7% |
| TERMINAL (d) | 35/36 (97%) | 31/35 (89%) | 34/38 (90%) | 30/36 (83%) |
| FIRST INCIDENCE | 422 | 454 | 493 | 444 |
| HC TUMORS SAME RTE | 259/300 (86%) | | | |
| HC TUMORS ALL RTES | 976/1149 (85%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|-----------|
| POLY 3 | P=0.057N | P=0.367N | P=0.367N | P=0.080N |
| POLY 1.5 | P=0.054N | P=0.414N | P=0.414N | P=0.083N |
| POLY 6 | P=0.063N | P=0.325N | P=0.325N | P=0.081N |
| COCH-ARM / FISHERS | P=0.056N | P=0.500N | P=0.500N | P=0.100N |
| MAX-ISO-POLY-3 | P=0.059N | P=0.225N | P=0.225N | P=0.038N* |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Adrenal Cortex
Adenoma**

TUMOR RATES

| | | | | |
|--------------------|-------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 1/50 (2%) | 1/50 (2%) | 2/50 (4%) |
| POLY-3 RATE (b) | 0/40.7 | 1/45.29 | 1/48.78 | 2/48.62 |
| POLY-3 PERCENT (g) | 0% | 2.2% | 2.1% | 4.1% |
| TERMINAL (d) | 0/31 (0%) | 1/38 (3%) | 1/42 (2%) | 2/43 (5%) |
| FIRST INCIDENCE | --- | 731 (T) | 731 (T) | 731 (T) |
| HC TUMORS SAME RTE | 2/299 (1%) | | | |
| HC TUMORS ALL RTES | 5/1244 (0%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----------|---------|---------|-----------|
| POLY 3 | P=0.195 | P=0.521 | P=0.536 | P=0.279 |
| POLY 1.5 | P=0.180 | P=0.514 | P=0.524 | P=0.264 |
| POLY 6 | P=0.212 | P=0.530 | P=0.548 | P=0.296 |
| COCH-ARM / FISHERS | P=0.153 | P=0.500 | P=0.500 | P=0.247 |
| MAX-ISO-POLY-3 | P=0.186 | P=0.184 | P=0.202 | P=0.116 |
| HISTCONT SAME RTE | P=0.051 | P=0.226 | P=0.235 | P=0.063 |
| HISTCONT ALL RTES | P<0.001** | P=0.101 | P=0.105 | P=0.007** |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Bone Marrow
Hemangiosarcoma**

TUMOR RATES

| | | | | |
|--------------------|-------------|-----------|-----------|-----------|
| OVERALL (a) | 1/50 (2%) | 0/50 (0%) | 0/50 (0%) | 2/49 (4%) |
| POLY-3 RATE (b) | 1/40.7 | 0/45.29 | 0/48.78 | 2/47.9 |
| POLY-3 PERCENT (g) | 2.5% | 0% | 0% | 4.2% |
| TERMINAL (d) | 1/31 (3%) | 0/38 (0%) | 0/42 (0%) | 1/43 (2%) |
| FIRST INCIDENCE | 731 (T) | --- | --- | 705 |
| HC TUMORS SAME RTE | 2/297 (1%) | | | |
| HC TUMORS ALL RTES | 7/1243 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|----------|----------|
| POLY 3 | P=0.254 | P=0.479N | P=0.464N | P=0.556 |
| POLY 1.5 | P=0.250 | P=0.486N | P=0.476N | P=0.534 |
| POLY 6 | P=0.258 | P=0.470N | P=0.452N | P=0.580 |
| COCH-ARM / FISHERS | P=0.241 | P=0.500N | P=0.500N | P=0.492 |
| MAX-ISO-POLY-3 | P=0.201 | P=0.158N | P=0.158N | P=0.342 |
| HISTCONT SAME RTE | P=0.130 | (e) | (e) | P=0.116 |
| HISTCONT ALL RTES | P=0.054 | (e) | (e) | P=0.038* |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|--------------------------------|----------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Harderian Gland Adenoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b) | 1/40.7 | 1/45.29 | 1/48.78 | 1/48.62 |
| POLY-3 PERCENT (g) | 2.5% | 2.2% | 2.1% | 2.1% |
| TERMINAL (d) | 1/31 (3%) | 1/38 (3%) | 1/42 (2%) | 1/43 (2%) |
| FIRST INCIDENCE | 731 (T) | 731 (T) | 731 (T) | 731 (T) |
| HC TUMORS SAME RTE | 29/300 (10%) | | | |
| HC TUMORS ALL RTES | 128/1249 (10%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.597N | P=0.736N | P=0.718N | P=0.719N |
| POLY 1.5 | P=0.609N | P=0.745N | P=0.733N | P=0.734N |
| POLY 6 | P=0.585N | P=0.726N | P=0.702N | P=0.703N |
| COCH-ARM / FISHERS | P=0.634 | P=0.753N | P=0.753N | P=0.753N |
| MAX-ISO-POLY-3 | P=0.693N | P=0.470N | P=0.452N | P=0.453N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|----------------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Harderian Gland Carcinoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 1/50 (2%) | 0/50 (0%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b) | 1/41.17 | 0/45.29 | 1/48.78 | 0/48.62 |
| POLY-3 PERCENT (g) | 2.4% | 0% | 2.1% | 0% |
| TERMINAL (d) | 0/31 (0%) | 0/38 (0%) | 1/42 (2%) | 0/43 (0%) |
| FIRST INCIDENCE | 592 | --- | 731 (T) | --- |
| HC TUMORS SAME RTE | 10/300 (3%) | | | |
| HC TUMORS ALL RTES | 33/1249 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.392N | P=0.481N | P=0.721N | P=0.467N |
| POLY 1.5 | P=0.396N | P=0.488N | P=0.735N | P=0.478N |
| POLY 6 | P=0.388N | P=0.474N | P=0.707N | P=0.455N |
| COCH-ARM / FISHERS | P=0.405N | P=0.500N | P=0.753N | P=0.500N |
| MAX-ISO-POLY-3 | P=0.255N | P=0.158N | P=0.455N | P=0.158N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|---|----------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Harderian Gland Carcinoma or Adenoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 2/50 (4%) | 1/50 (2%) | 2/50 (4%) | 1/50 (2%) |
| POLY-3 RATE (b) | 2/41.17 | 1/45.29 | 2/48.78 | 1/48.62 |
| POLY-3 PERCENT (g) | 4.9% | 2.2% | 4.1% | 2.1% |
| TERMINAL (d) | 1/31 (3%) | 1/38 (3%) | 2/42 (5%) | 1/43 (2%) |
| FIRST INCIDENCE | 592 | 731 (T) | 731 (T) | 731 (T) |
| HC TUMORS SAME RTE | 38/300 (13%) | | | |
| HC TUMORS ALL RTES | 160/1249 (13%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.401N | P=0.467N | P=0.631N | P=0.442N |
| POLY 1.5 | P=0.415N | P=0.478N | P=0.653N | P=0.462N |
| POLY 6 | P=0.387N | P=0.455N | P=0.609N | P=0.422N |
| COCH-ARM / FISHERS | P=0.444N | P=0.500N | P=0.691N | P=0.500N |
| MAX-ISO-POLY-3 | P=0.405N | P=0.262N | P=0.435N | P=0.251N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Islets, Pancreatic
Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 0/40.7 | 0/45.29 | 0/48.78 | 0/48.62 |
| POLY-3 PERCENT (g) | 0% | 0% | 0% | 0% |
| TERMINAL (d) | 0/31 (0%) | 0/38 (0%) | 0/42 (0%) | 0/43 (0%) |
| FIRST INCIDENCE | --- | --- | --- | --- |
| HC TUMORS SAME RTE | 2/295 (1%) | | | |
| HC TUMORS ALL RTES | 12/1228 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----|-----|-----|-----|
| POLY 3 | (e) | (e) | (e) | (e) |
| POLY 1.5 | (e) | (e) | (e) | (e) |
| POLY 6 | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3 | (e) | (e) | (e) | (e) |
| HISTCONT SAME RTE | (e) | (e) | (e) | (e) |
| HISTCONT ALL RTES | (e) | (e) | (e) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Islets, Pancreatic
Carcinoma or Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 0/40.7 | 0/45.29 | 0/48.78 | 0/48.62 |
| POLY-3 PERCENT (g) | 0% | 0% | 0% | 0% |
| TERMINAL (d) | 0/31 (0%) | 0/38 (0%) | 0/42 (0%) | 0/43 (0%) |
| FIRST INCIDENCE | --- | --- | --- | --- |
| HC TUMORS SAME RTE | 4/295 (1%) | | | |
| HC TUMORS ALL RTES | 16/1228 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----|-----|-----|-----|
| POLY 3 | (e) | (e) | (e) | (e) |
| POLY 1.5 | (e) | (e) | (e) | (e) |
| POLY 6 | (e) | (e) | (e) | (e) |
| COCH-ARM / FISHERS | (e) | (e) | (e) | (e) |
| MAX-ISO-POLY-3 | (e) | (e) | (e) | (e) |
| HISTCONT SAME RTE | (e) | (e) | (e) | (e) |
| HISTCONT ALL RTES | (e) | (e) | (e) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Liver Hemangiosarcoma | | | | |
| TUMOR RATES | | | | |
| OVERALL (a) | 2/50 (4%) | 0/50 (0%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b) | 2/40.7 | 0/45.29 | 0/48.78 | 1/48.62 |
| POLY-3 PERCENT (g) | 4.9% | 0% | 0% | 2.1% |
| TERMINAL (d) | 2/31 (7%) | 0/38 (0%) | 0/42 (0%) | 1/43 (2%) |
| FIRST INCIDENCE | 731 (T) | --- | --- | 731 (T) |
| HC TUMORS SAME RTE | 2/299 (1%) | | | |
| HC TUMORS ALL RTES | 11/1245 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.475N | P=0.214N | P=0.200N | P=0.439N |
| POLY 1.5 | P=0.469N | P=0.222N | P=0.212N | P=0.460N |
| POLY 6 | P=0.484N | P=0.205N | P=0.187N | P=0.416N |
| COCH-ARM / FISHERS | P=0.461N | P=0.247N | P=0.247N | P=0.500N |
| MAX-ISO-POLY-3 | P=0.124N | P=0.075N | P=0.075N | P=0.249N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hepatocellular Adenoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 14/50 (28%) | 16/50 (32%) | 17/50 (34%) | 22/50 (44%) |
| POLY-3 RATE (b) | 14/41.44 | 16/46.1 | 17/49.16 | 22/48.66 |
| POLY-3 PERCENT (g) | 33.8% | 34.7% | 34.6% | 45.2% |
| TERMINAL (d) | 10/31 (32%) | 12/38 (32%) | 15/42 (36%) | 21/43 (49%) |
| FIRST INCIDENCE | 666 | 639 | 656 | 721 |
| HC TUMORS SAME RTE | 82/299 (27%) | | | |
| HC TUMORS ALL RTES | 345/1245 (28%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|----------|---------|
| POLY 3 | P=0.129 | P=0.553 | P=0.556 | P=0.187 |
| POLY 1.5 | P=0.098 | P=0.503 | P=0.479 | P=0.138 |
| POLY 6 | P=0.162 | P=0.572N | P=0.547N | P=0.243 |
| COCH-ARM / FISHERS | P=0.051 | P=0.414 | P=0.333 | P=0.072 |
| MAX-ISO-POLY-3 | P=0.208 | P=0.464 | P=0.470 | P=0.151 |
| HISTCONT SAME RTE | P=0.077 | P=0.438 | P=0.433 | P=0.128 |
| HISTCONT ALL RTES | P=0.238 | P=0.537 | P=0.535 | P=0.179 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hepatocellular Carcinoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|------------|------------|-----------|
| OVERALL (a) | 7/50 (14%) | 5/50 (10%) | 9/50 (18%) | 2/50 (4%) |
| POLY-3 RATE (b) | 7/40.7 | 5/45.7 | 9/49.35 | 2/48.7 |
| POLY-3 PERCENT (g) | 17.2% | 10.9% | 18.2% | 4.1% |
| TERMINAL (d) | 7/31 (23%) | 3/38 (8%) | 5/42 (12%) | 0/43 (0%) |
| FIRST INCIDENCE | 731 (T) | 645 | 653 | 721 |
| HC TUMORS SAME RTE | 34/299 (11%) | | | |
| HC TUMORS ALL RTES | 131/1245 (11%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|-----------|----------|----------|-----------|
| POLY 3 | P=0.057N | P=0.300N | P=0.558 | P=0.044N* |
| POLY 1.5 | P=0.071N | P=0.328N | P=0.499 | P=0.055N |
| POLY 6 | P=0.045N* | P=0.268N | P=0.594N | P=0.035N* |
| COCH-ARM / FISHERS | P=0.108N | P=0.380N | P=0.393 | P=0.080N |
| MAX-ISO-POLY-3 | P=0.070N | P=0.215N | P=0.452 | P=0.029N* |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hepatocellular Carcinoma or Hepatocellular Adenoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 20/50 (40%) | 20/50 (40%) | 23/50 (46%) | 23/50 (46%) |
| POLY-3 RATE (b) | 20/41.44 | 20/46.51 | 23/49.63 | 23/48.7 |
| POLY-3 PERCENT (g) | 48.3% | 43% | 46.3% | 47.2% |
| TERMINAL (d) | 16/31 (52%) | 14/38 (37%) | 18/42 (43%) | 21/43 (49%) |
| FIRST INCIDENCE | 666 | 639 | 653 | 721 |
| HC TUMORS SAME RTE | 104/299 (35%) | | | |
| HC TUMORS ALL RTES | 419/1245 (34%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.502 | P=0.389N | P=0.511N | P=0.546N |
| POLY 1.5 | P=0.422 | P=0.460N | P=0.545 | P=0.525 |
| POLY 6 | P=0.517N | P=0.311N | P=0.401N | P=0.451N |
| COCH-ARM / FISHERS | P=0.265 | P=0.581N | P=0.343 | P=0.343 |
| MAX-ISO-POLY-3 | P=0.634N | P=0.319N | P=0.431N | P=0.463N |
| HISTCONT SAME RTE | P=0.241 | P=0.460 | P=0.331 | P=0.308 |
| HISTCONT ALL RTES | P=0.398 | P=0.507 | P=0.431 | P=0.418 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Liver
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

TUMOR RATES

| | | | | |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 20/50 (40%) | 20/50 (40%) | 23/50 (46%) | 23/50 (46%) |
| POLY-3 RATE (b) | 20/41.44 | 20/46.51 | 23/49.63 | 23/48.7 |
| POLY-3 PERCENT (g) | 48.3% | 43% | 46.3% | 47.2% |
| TERMINAL (d) | 16/31 (52%) | 14/38 (37%) | 18/42 (43%) | 21/43 (49%) |
| FIRST INCIDENCE | 666 | 639 | 653 | 721 |
| HC TUMORS SAME RTE | 104/299 (35%) | | | |
| HC TUMORS ALL RTES | 421/1245 (34%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.502 | P=0.389N | P=0.511N | P=0.546N |
| POLY 1.5 | P=0.422 | P=0.460N | P=0.545 | P=0.525 |
| POLY 6 | P=0.517N | P=0.311N | P=0.401N | P=0.451N |
| COCH-ARM / FISHERS | P=0.265 | P=0.581N | P=0.343 | P=0.343 |
| MAX-ISO-POLY-3 | P=0.634N | P=0.319N | P=0.431N | P=0.463N |
| HISTCONT SAME RTE | P=0.241 | P=0.460 | P=0.331 | P=0.308 |
| HISTCONT ALL RTES | P=0.407 | P=0.511 | P=0.435 | P=0.421 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Lung
Alveolar/Bronchiolar Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 6/50 (12%) | 1/50 (2%) | 2/50 (4%) | 4/50 (8%) |
| POLY-3 RATE (b) | 6/40.92 | 1/45.29 | 2/48.88 | 4/48.62 |
| POLY-3 PERCENT (g) | 14.7% | 2.2% | 4.1% | 8.2% |
| TERMINAL (d) | 5/31 (16%) | 1/38 (3%) | 1/42 (2%) | 4/43 (9%) |
| FIRST INCIDENCE | 674 | 731 (T) | 704 | 731 (T) |
| HC TUMORS SAME RTE | 15/300 (5%) | | | |
| HC TUMORS ALL RTES | 65/1248 (5%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|-----------|----------|----------|
| POLY 3 | P=0.411N | P=0.041N* | P=0.084N | P=0.268N |
| POLY 1.5 | P=0.420N | P=0.046N* | P=0.099N | P=0.301N |
| POLY 6 | P=0.403N | P=0.036N* | P=0.071N | P=0.234N |
| COCH-ARM / FISHERS | P=0.442N | P=0.056N | P=0.134N | P=0.370N |
| MAX-ISO-POLY-3 | P=0.079N | P=0.021N* | P=0.053N | P=0.189N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Lung
Alveolar/Bronchiolar Carcinoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|------------|-----------|-----------|
| OVERALL (a) | 0/50 (0%) | 4/50 (8%) | 2/50 (4%) | 2/50 (4%) |
| POLY-3 RATE (b) | 0/40.7 | 4/45.29 | 2/48.88 | 2/48.62 |
| POLY-3 PERCENT (g) | 0% | 8.8% | 4.1% | 4.1% |
| TERMINAL (d) | 0/31 (0%) | 4/38 (11%) | 1/42 (2%) | 2/43 (5%) |
| FIRST INCIDENCE | --- | 731 (T) | 704 | 731 (T) |
| HC TUMORS SAME RTE | 8/300 (3%) | | | |
| HC TUMORS ALL RTES | 47/1248 (4%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|---------|---------|
| POLY 3 | P=0.515 | P=0.075 | P=0.280 | P=0.279 |
| POLY 1.5 | P=0.476 | P=0.070 | P=0.265 | P=0.264 |
| POLY 6 | P=0.556 | P=0.081 | P=0.297 | P=0.296 |
| COCH-ARM / FISHERS | P=0.404 | P=0.059 | P=0.247 | P=0.247 |
| MAX-ISO-POLY-3 | P=0.195 | P=0.031* | P=0.117 | P=0.116 |
| HISTCONT SAME RTE | P=0.234 | P=0.034* | P=0.144 | P=0.142 |
| HISTCONT ALL RTES | P=0.224 | P=0.032* | P=0.136 | P=0.134 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Lung
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

TUMOR RATES

| | | | | |
|--------------------|---------------|------------|-----------|------------|
| OVERALL (a) | 6/50 (12%) | 5/50 (10%) | 3/50 (6%) | 6/50 (12%) |
| POLY-3 RATE (b) | 6/40.92 | 5/45.29 | 3/48.88 | 6/48.62 |
| POLY-3 PERCENT (g) | 14.7% | 11% | 6.1% | 12.3% |
| TERMINAL (d) | 5/31 (16%) | 5/38 (13%) | 2/42 (5%) | 6/43 (14%) |
| FIRST INCIDENCE | 674 | 731 (T) | 704 | 731 (T) |
| HC TUMORS SAME RTE | 23/300 (8%) | | | |
| HC TUMORS ALL RTES | 107/1248 (9%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.481N | P=0.429N | P=0.163N | P=0.496N |
| POLY 1.5 | P=0.508N | P=0.454N | P=0.188N | P=0.540N |
| POLY 6 | P=0.456N | P=0.403N | P=0.140N | P=0.450N |
| COCH-ARM / FISHERS | P=0.563 | P=0.500N | P=0.243N | P=0.620N |
| MAX-ISO-POLY-3 | P=0.370N | P=0.317N | P=0.109N | P=0.383N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|--------------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Mammary Gland Carcinoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 1/50 (2%) | 2/50 (4%) | 0/50 (0%) | 0/50 (0%) |
| POLY-3 RATE (b) | 1/41.13 | 2/45.88 | 0/48.78 | 0/48.62 |
| POLY-3 PERCENT (g) | 2.4% | 4.4% | 0% | 0% |
| TERMINAL (d) | 0/31 (0%) | 0/38 (0%) | 0/42 (0%) | 0/43 (0%) |
| FIRST INCIDENCE | 607 | 586 | --- | --- |
| HC TUMORS SAME RTE | 3/300 (1%) | | | |
| HC TUMORS ALL RTES | 16/1249 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.164N | P=0.538 | P=0.466N | P=0.467N |
| POLY 1.5 | P=0.171N | P=0.524 | P=0.478N | P=0.478N |
| POLY 6 | P=0.157N | P=0.553 | P=0.455N | P=0.455N |
| COCH-ARM / FISHERS | P=0.188N | P=0.500 | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3 | P=0.194N | P=0.322 | P=0.158N | P=0.158N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|--------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Ovary | | | | |
| Cystadenoma | | | | |
| TUMOR RATES | | | | |
| OVERALL (a) | 2/50 (4%) | 3/50 (6%) | 1/50 (2%) | 1/49 (2%) |
| POLY-3 RATE (b) | 2/40.7 | 3/45.39 | 1/48.78 | 1/47.8 |
| POLY-3 PERCENT (g) | 4.9% | 6.6% | 2.1% | 2.1% |
| TERMINAL (d) | 2/31 (7%) | 2/38 (5%) | 1/42 (2%) | 1/43 (2%) |
| FIRST INCIDENCE | 731 (T) | 704 | 731 (T) | 731 (T) |
| HC TUMORS SAME RTE | 17/291 (6%) | | | |
| HC TUMORS ALL RTES | 46/1221 (4%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.236N | P=0.550 | P=0.437N | P=0.444N |
| POLY 1.5 | P=0.252N | P=0.532 | P=0.459N | P=0.466N |
| POLY 6 | P=0.220N | P=0.570 | P=0.416N | P=0.421N |
| COCH-ARM / FISHERS | P=0.285N | P=0.500 | P=0.500N | P=0.508N |
| MAX-ISO-POLY-3 | P=0.332N | P=0.375 | P=0.249N | P=0.253N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma**

TUMOR RATES

| | | | | |
|--------------------|--------------|-----------|------------|------------|
| OVERALL (a) | 6/49 (12%) | 4/50 (8%) | 8/50 (16%) | 7/50 (14%) |
| POLY-3 RATE (b) | 6/39.99 | 4/45.45 | 8/48.78 | 7/48.73 |
| POLY-3 PERCENT (g) | 15% | 8.8% | 16.4% | 14.4% |
| TERMINAL (d) | 4/30 (13%) | 3/38 (8%) | 8/42 (19%) | 6/43 (14%) |
| FIRST INCIDENCE | 674 | 690 | 731 (T) | 705 |
| HC TUMORS SAME RTE | 41/294 (14%) | | | |
| HC TUMORS ALL RTES | 97/1216 (8%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|---------|----------|
| POLY 3 | P=0.447 | P=0.291N | P=0.544 | P=0.585N |
| POLY 1.5 | P=0.407 | P=0.314N | P=0.496 | P=0.603 |
| POLY 6 | P=0.488 | P=0.268N | P=0.591 | P=0.536N |
| COCH-ARM / FISHERS | P=0.330 | P=0.357N | P=0.403 | P=0.516 |
| MAX-ISO-POLY-3 | P=0.519 | P=0.202N | P=0.433 | P=0.468N |
| HISTCONT SAME RTE | P=0.625 | P=1.000 | P=0.561 | P=1.000 |
| HISTCONT ALL RTES | P=0.148 | P=0.628 | P=0.187 | P=0.279 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Skin
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 1/50 (2%) | 2/50 (4%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b) | 1/41.28 | 2/45.83 | 0/48.78 | 1/48.62 |
| POLY-3 PERCENT (g) | 2.4% | 4.4% | 0% | 2.1% |
| TERMINAL (d) | 0/31 (0%) | 1/38 (3%) | 0/42 (0%) | 1/43 (2%) |
| FIRST INCIDENCE | 549 | 563 | --- | 731 (T) |
| HC TUMORS SAME RTE | 14/300 (5%) | | | |
| HC TUMORS ALL RTES | 53/1249 (4%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.465N | P=0.536 | P=0.467N | P=0.723N |
| POLY 1.5 | P=0.476N | P=0.524 | P=0.478N | P=0.736N |
| POLY 6 | P=0.454N | P=0.551 | P=0.456N | P=0.708N |
| COCH-ARM / FISHERS | P=0.500N | P=0.500 | P=0.500N | P=0.753N |
| MAX-ISO-POLY-3 | P=0.386N | P=0.320 | P=0.158N | P=0.456N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Skin
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 1/50 (2%) | 2/50 (4%) | 0/50 (0%) | 1/50 (2%) |
| POLY-3 RATE (b) | 1/41.28 | 2/45.83 | 0/48.78 | 1/48.62 |
| POLY-3 PERCENT (g) | 2.4% | 4.4% | 0% | 2.1% |
| TERMINAL (d) | 0/31 (0%) | 1/38 (3%) | 0/42 (0%) | 1/43 (2%) |
| FIRST INCIDENCE | 549 | 563 | --- | 731 (T) |
| HC TUMORS SAME RTE | 14/300 (5%) | | | |
| HC TUMORS ALL RTES | 53/1249 (4%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.465N | P=0.536 | P=0.467N | P=0.723N |
| POLY 1.5 | P=0.476N | P=0.524 | P=0.478N | P=0.736N |
| POLY 6 | P=0.454N | P=0.551 | P=0.456N | P=0.708N |
| COCH-ARM / FISHERS | P=0.500N | P=0.500 | P=0.500N | P=0.753N |
| MAX-ISO-POLY-3 | P=0.386N | P=0.320 | P=0.158N | P=0.456N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Skin | | | | |
| Hemangiosarcoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 0/50 (0%) | 1/50 (2%) | 1/50 (2%) | 0/50 (0%) |
| POLY-3 RATE (b) | 0/40.7 | 1/45.29 | 1/48.78 | 0/48.62 |
| POLY-3 PERCENT (g) | 0% | 2.2% | 2.1% | 0% |
| TERMINAL (d) | 0/31 (0%) | 1/38 (3%) | 1/42 (2%) | 0/43 (0%) |
| FIRST INCIDENCE | --- | 731 (T) | 731 (T) | --- |
| HC TUMORS SAME RTE | 3/300 (1%) | | | |
| HC TUMORS ALL RTES | 17/1249 (1%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|---------|-----|
| POLY 3 | P=0.544N | P=0.521 | P=0.536 | (e) |
| POLY 1.5 | P=0.561N | P=0.514 | P=0.524 | (e) |
| POLY 6 | P=0.525N | P=0.530 | P=0.548 | (e) |
| COCH-ARM / FISHERS | P=0.595N | P=0.500 | P=0.500 | (e) |
| MAX-ISO-POLY-3 | P=0.439N | P=0.184 | P=0.202 | (e) |
| HISTCONT SAME RTE | (h) | (h) | (h) | (e) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (e) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|-------------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Spleen Hemangiosarcoma | | | | |
| TUMOR RATES | | | | |
| OVERALL (a) | 1/50 (2%) | 0/50 (0%) | 1/50 (2%) | 4/50 (8%) |
| POLY-3 RATE (b) | 1/40.7 | 0/45.29 | 1/48.78 | 4/48.73 |
| POLY-3 PERCENT (g) | 2.5% | 0% | 2.1% | 8.2% |
| TERMINAL (d) | 1/31 (3%) | 0/38 (0%) | 1/42 (2%) | 3/43 (7%) |
| FIRST INCIDENCE | 731 (T) | --- | 731 (T) | 705 |
| HC TUMORS SAME RTE | 3/297 (1%) | | | |
| HC TUMORS ALL RTES | 24/1230 (2%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.041* | P=0.479N | P=0.718N | P=0.239 |
| POLY 1.5 | P=0.038* | P=0.486N | P=0.733N | P=0.217 |
| POLY 6 | P=0.044* | P=0.470N | P=0.702N | P=0.265 |
| COCH-ARM / FISHERS | P=0.034* | P=0.500N | P=0.753N | P=0.181 |
| MAX-ISO-POLY-3 | P=0.064 | P=0.158N | P=0.452N | P=0.141 |
| HISTCONT SAME RTE | P=0.016* | (e) | P=0.349 | P=0.026* |
| HISTCONT ALL RTES | P=0.062 | (e) | P=1.000 | P=0.044* |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**Stomach, Forestomach
Squamous Cell Papilloma**

TUMOR RATES

| | # | # | # | # |
|--------------------|--------------|-----------|-----------|-----------|
| OVERALL (a) | 1/50 (2%) | 2/50 (4%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b) | 1/40.7 | 2/45.29 | 1/48.78 | 1/48.62 |
| POLY-3 PERCENT (g) | 2.5% | 4.4% | 2.1% | 2.1% |
| TERMINAL (d) | 1/31 (3%) | 2/38 (5%) | 1/42 (2%) | 1/43 (2%) |
| FIRST INCIDENCE | 731 (T) | 731 (T) | 731 (T) | 731 (T) |
| HC TUMORS SAME RTE | 3/300 (1%) | | | |
| HC TUMORS ALL RTES | 20/1249 (2%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.476N | P=0.537 | P=0.718N | P=0.719N |
| POLY 1.5 | P=0.494N | P=0.524 | P=0.733N | P=0.734N |
| POLY 6 | P=0.458N | P=0.552 | P=0.702N | P=0.703N |
| COCH-ARM / FISHERS | P=0.531N | P=0.500 | P=0.753N | P=0.753N |
| MAX-ISO-POLY-3 | P=0.560N | P=0.321 | P=0.452N | P=0.453N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|----------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Uterus | | | | |
| Polyp Stromal | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 1/50 (2%) | 3/50 (6%) | 4/50 (8%) | 0/50 (0%) |
| POLY-3 RATE (b) | 1/40.7 | 3/45.29 | 4/49.06 | 0/48.62 |
| POLY-3 PERCENT (g) | 2.5% | 6.6% | 8.2% | 0% |
| TERMINAL (d) | 1/31 (3%) | 3/38 (8%) | 3/42 (7%) | 0/43 (0%) |
| FIRST INCIDENCE | 731 (T) | 731 (T) | 656 | --- |
| HC TUMORS SAME RTE | 14/300 (5%) | | | |
| HC TUMORS ALL RTES | 33/1249 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|---------|----------|
| POLY 3 | P=0.224N | P=0.344 | P=0.241 | P=0.465N |
| POLY 1.5 | P=0.253N | P=0.330 | P=0.218 | P=0.477N |
| POLY 6 | P=0.196N | P=0.360 | P=0.267 | P=0.452N |
| COCH-ARM / FISHERS | P=0.313N | P=0.309 | P=0.181 | P=0.500N |
| MAX-ISO-POLY-3 | P=0.172N | P=0.194 | P=0.143 | P=0.158N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|---|--------------|------------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| Uterus | | | | |
| Sarcoma Stromal or Polyp Stromal | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 1/50 (2%) | 4/50 (8%) | 4/50 (8%) | 0/50 (0%) |
| POLY-3 RATE (b) | 1/40.7 | 4/45.29 | 4/49.06 | 0/48.62 |
| POLY-3 PERCENT (g) | 2.5% | 8.8% | 8.2% | 0% |
| TERMINAL (d) | 1/31 (3%) | 4/38 (11%) | 3/42 (7%) | 0/43 (0%) |
| FIRST INCIDENCE | 731 (T) | 731 (T) | 656 | --- |
| HC TUMORS SAME RTE | 16/300 (5%) | | | |
| HC TUMORS ALL RTES | 40/1249 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|---------|----------|
| POLY 3 | P=0.175N | P=0.213 | P=0.241 | P=0.465N |
| POLY 1.5 | P=0.203N | P=0.200 | P=0.218 | P=0.477N |
| POLY 6 | P=0.149N | P=0.227 | P=0.267 | P=0.452N |
| COCH-ARM / FISHERS | P=0.263N | P=0.181 | P=0.181 | P=0.500N |
| MAX-ISO-POLY-3 | P=0.148N | P=0.116 | P=0.143 | P=0.158N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Hemangiosarcoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 2/50 (4%) | 2/50 (4%) | 2/50 (4%) | 4/50 (8%) |
| POLY-3 RATE (b) | 2/40.7 | 2/45.39 | 2/48.88 | 4/48.73 |
| POLY-3 PERCENT (g) | 4.9% | 4.4% | 4.1% | 8.2% |
| TERMINAL (d) | 2/31 (7%) | 1/38 (3%) | 1/42 (2%) | 3/43 (7%) |
| FIRST INCIDENCE | 731 (T) | 704 | 704 | 705 |
| HC TUMORS SAME RTE | 12/300 (4%) | | | |
| HC TUMORS ALL RTES | 60/1249 (5%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|----------|---------|
| POLY 3 | P=0.279 | P=0.654N | P=0.626N | P=0.423 |
| POLY 1.5 | P=0.260 | P=0.668N | P=0.650N | P=0.393 |
| POLY 6 | P=0.301 | P=0.637N | P=0.600N | P=0.458 |
| COCH-ARM / FISHERS | P=0.221 | P=0.691N | P=0.691N | P=0.339 |
| MAX-ISO-POLY-3 | P=0.391 | P=0.457N | P=0.431N | P=0.287 |
| HISTCONT SAME RTE | P=0.215 | P=1.000 | P=1.000 | P=0.176 |
| HISTCONT ALL RTES | P=0.454 | P=1.000 | P=1.000 | P=0.327 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

**All Organs
Hemangiosarcoma or Hemangioma**

| TUMOR RATES | # | # | # | # |
|--------------------|--------------|-----------|-----------|------------|
| OVERALL (a) | 2/50 (4%) | 2/50 (4%) | 2/50 (4%) | 5/50 (10%) |
| POLY-3 RATE (b) | 2/40.7 | 2/45.39 | 2/48.88 | 5/48.73 |
| POLY-3 PERCENT (g) | 4.9% | 4.4% | 4.1% | 10.3% |
| TERMINAL (d) | 2/31 (7%) | 1/38 (3%) | 1/42 (2%) | 4/43 (9%) |
| FIRST INCIDENCE | 731 (T) | 704 | 704 | 705 |
| HC TUMORS SAME RTE | 15/300 (5%) | | | |
| HC TUMORS ALL RTES | 79/1249 (6%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|---------|----------|----------|---------|
| POLY 3 | P=0.153 | P=0.654N | P=0.626N | P=0.296 |
| POLY 1.5 | P=0.139 | P=0.668N | P=0.650N | P=0.267 |
| POLY 6 | P=0.167 | P=0.637N | P=0.600N | P=0.330 |
| COCH-ARM / FISHERS | P=0.114 | P=0.691N | P=0.691N | P=0.218 |
| MAX-ISO-POLY-3 | P=0.241 | P=0.457N | P=0.431N | P=0.197 |
| HISTCONT SAME RTE | P=0.164 | P=1.000 | P=1.000 | P=0.149 |
| HISTCONT ALL RTES | P=0.277 | P=1.000 | P=1.000 | P=0.237 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|----------------------------|--------------|-----------|-----------|-----------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Histiocytic Sarcoma | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 2/50 (4%) | 1/50 (2%) | 1/50 (2%) | 1/50 (2%) |
| POLY-3 RATE (b) | 2/40.8 | 1/46.22 | 1/48.94 | 1/48.62 |
| POLY-3 PERCENT (g) | 4.9% | 2.2% | 2% | 2.1% |
| TERMINAL (d) | 1/31 (3%) | 0/38 (0%) | 0/42 (0%) | 1/43 (2%) |
| FIRST INCIDENCE | 705 | 298 | 690 | 731 (T) |
| HC TUMORS SAME RTE | 8/300 (3%) | | | |
| HC TUMORS ALL RTES | 31/1249 (3%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.384N | P=0.457N | P=0.437N | P=0.439N |
| POLY 1.5 | P=0.392N | P=0.471N | P=0.459N | P=0.460N |
| POLY 6 | P=0.377N | P=0.442N | P=0.415N | P=0.418N |
| COCH-ARM / FISHERS | P=0.409N | P=0.500N | P=0.500N | P=0.500N |
| MAX-ISO-POLY-3 | P=0.371N | P=0.257N | P=0.249N | P=0.250N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------|---------|--------|--------|---------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |

All Organs
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type

| TUMOR RATES | # | # | # | # |
|--------------------|----------------|-------------|-------------|-------------|
| OVERALL (a) | 12/50 (24%) | 12/50 (24%) | 10/50 (20%) | 12/50 (24%) |
| POLY-3 RATE (b) | 12/41.13 | 12/46.53 | 10/49.23 | 12/49.21 |
| POLY-3 PERCENT (g) | 29.2% | 25.8% | 20.3% | 24.4% |
| TERMINAL (d) | 10/31 (32%) | 8/38 (21%) | 7/42 (17%) | 9/43 (21%) |
| FIRST INCIDENCE | 673 | 514 | 656 | 648 |
| HC TUMORS SAME RTE | 64/300 (21%) | | | |
| HC TUMORS ALL RTES | 284/1249 (23%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.362N | P=0.455N | P=0.234N | P=0.393N |
| POLY 1.5 | P=0.414N | P=0.505N | P=0.289N | P=0.463N |
| POLY 6 | P=0.312N | P=0.399N | P=0.185N | P=0.322N |
| COCH-ARM / FISHERS | P=0.523N | P=0.592N | P=0.405N | P=0.592N |
| MAX-ISO-POLY-3 | P=0.404N | P=0.368N | P=0.186N | P=0.320N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|----------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Benign Tumors | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 24/50 (48%) | 27/50 (54%) | 26/50 (52%) | 34/50 (68%) |
| POLY-3 RATE (b) | 24/42.44 | 27/46.14 | 26/49.27 | 34/48.8 |
| POLY-3 PERCENT (g) | 56.6% | 58.5% | 52.8% | 69.7% |
| TERMINAL (d) | 18/31 (58%) | 22/38 (58%) | 23/42 (55%) | 31/43 (72%) |
| FIRST INCIDENCE | 432 | 639 | 656 | 705 |
| HC TUMORS SAME RTE | 170/300 (57%) | | | |
| HC TUMORS ALL RTES | 644/1249 (52%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|---------|----------|----------|
| POLY 3 | P=0.106 | P=0.511 | P=0.439N | P=0.134 |
| POLY 1.5 | P=0.071 | P=0.449 | P=0.542N | P=0.086 |
| POLY 6 | P=0.146 | P=0.583 | P=0.343N | P=0.200 |
| COCH-ARM / FISHERS | P=0.029* | P=0.345 | P=0.421 | P=0.034* |
| MAX-ISO-POLY-3 | P=0.165 | P=0.425 | P=0.366N | P=0.105 |
| HISTCONT SAME RTE | P=0.198 | P=0.551 | P=1.000 | P=0.129 |
| HISTCONT ALL RTES | P=0.189 | P=0.538 | P=1.000 | P=0.121 |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|-------------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Malignant Tumors | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 27/50 (54%) | 25/50 (50%) | 23/50 (46%) | 23/50 (46%) |
| POLY-3 RATE (b) | 27/44.21 | 25/49.01 | 23/50 | 23/49.38 |
| POLY-3 PERCENT (g) | 61.1% | 51% | 46% | 46.6% |
| TERMINAL (d) | 18/31 (58%) | 15/38 (40%) | 15/42 (36%) | 17/43 (40%) |
| FIRST INCIDENCE | 432 | 298 | 653 | 648 |
| HC TUMORS SAME RTE | 149/300 (50%) | | | |
| HC TUMORS ALL RTES | 629/1249 (50%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|----------|----------|
| POLY 3 | P=0.122N | P=0.220N | P=0.103N | P=0.114N |
| POLY 1.5 | P=0.151N | P=0.278N | P=0.146N | P=0.155N |
| POLY 6 | P=0.101N | P=0.172N | P=0.072N | P=0.084N |
| COCH-ARM / FISHERS | P=0.237N | P=0.421N | P=0.274N | P=0.274N |
| MAX-ISO-POLY-3 | P=0.144N | P=0.175N | P=0.082N | P=0.090N |
| HISTCONT SAME RTE | (h) | (h) | (h) | (h) |
| HISTCONT ALL RTES | (h) | (h) | (h) | (h) |

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

| DOSE | Females | | | |
|------------------------------------|----------------|-------------|-------------|-------------|
| | CONTROL | 30 PPM | 60 PPM | 120 PPM |
| All Organs | | | | |
| Malignant and Benign Tumors | | | | |
| TUMOR RATES | # | # | # | # |
| OVERALL (a) | 40/50 (80%) | 38/50 (76%) | 38/50 (76%) | 43/50 (86%) |
| POLY-3 RATE (b) | 40/44.71 | 38/49.17 | 38/50 | 43/49.38 |
| POLY-3 PERCENT (g) | 89.5% | 77.3% | 76% | 87.1% |
| TERMINAL (d) | 28/31 (90%) | 27/38 (71%) | 30/42 (71%) | 37/43 (86%) |
| FIRST INCIDENCE | 432 | 298 | 653 | 648 |
| HC TUMORS SAME RTE | 240/300 (80%) | | | |
| HC TUMORS ALL RTES | 939/1249 (75%) | | | |

STATISTICAL TESTS

| | | | | |
|--------------------|----------|----------|-----------|----------|
| POLY 3 | P=0.484 | P=0.089N | P=0.067N | P=0.483N |
| POLY 1.5 | P=0.399 | P=0.161N | P=0.136N | P=0.619 |
| POLY 6 | P=0.545 | P=0.051N | P=0.035N* | P=0.362N |
| COCH-ARM / FISHERS | P=0.212 | P=0.405N | P=0.405N | P=0.298 |
| MAX-ISO-POLY-3 | P=0.204N | P=0.059N | P=0.046N* | P=0.358N |
| HISTCONT SAME RTE | P=0.392 | P=1.000 | P=1.000 | P=0.313 |
| HISTCONT ALL RTES | P=0.407 | P=0.629 | P=1.000 | P=0.367 |

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (e) Value of Statistic cannot be computed.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (h) Value of Historical Controls statistic is only calculated when Poly-3 trend is positive and when there is more than one tumor in the treatment groups.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***